Hypertension Trial, Recruiting NCT06307574 Sponsor: University of Arizona Condition: Hypertension
Back to Hypertension

Hypertension Trial, Recruiting

NCT06307574
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who are 60 years of age or older
  • People who live independently in the community (not in a care facility)
  • People who speak and understand English fluently
  • People who have adequate vision and hearing ability (as reported by themselves)
  • People who feel they have some challenges with memory, thinking, or concentration
  • People who independently manage at least one prescribed blood pressure medication
  • People who own and regularly use a smartphone
  • People who have no history of major depression or other mental health diagnoses (as reported by themselves)
  • People who have not been diagnosed with dementia or a neurological condition such as stroke, traumatic brain injury, or Parkinson's disease (as reported by themselves)
  • People whose scores on two specific memory and thinking tests fall within a certain range — one test called the TICS-M (score between 27–37) and another called the MoCA (score between 20–26) (confirm with trial site)
  • People who are willing to take part in the study for at least 4 months

Who may not be able to join:

  • People who have been diagnosed with dementia
  • People who live in an assisted living facility or a skilled nursing facility

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 8 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Kathleen Insel, PhD, University of Arizona

Phone: 520-626-6220

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
University of Arizona
Registry
ClinicalTrials.gov
Start date
29 February 2024
Est. completion
30 April 2026

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Change in medication adherence measured by the Medication Event Monitoring System (MEMS® Cap); Change in self-reported medication adherence measured by the Medication Adherence Report Scale-5 (MARS-5© Professor Rob Horne)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 8 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov